This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Announces Clinical Data Presentations At Upcoming 55th ASH Annual Meeting And Exposition

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted antibody-based anticancer therapeutics, today provided information on the clinical data presentations related to the Company to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 7-10, 2013 in New Orleans, LA.

There will be an oral presentation on SAR650984, the CD38-targeting therapeutic antibody developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies.

  • Title: "SAR650984, a CD38 Monoclonal Antibody in Patients with Selected CD38+ Hematological Malignancies – Data from a Dose-Escalation Phase I Study" (Abstract #284).
  • Presentation time: Dec. 9 at 7:15 am CST (Session #653).

There also will be an oral presentation on BT062, the CD138-targeting antibody-drug conjugate (ADC) in development through the Company’s collaboration with Biotest.

  • Title: "Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Len/Dex-Refractory Patients" (Abstract #758).
  • Presentation time: Dec. 9 at 6:30 pm CST (Session #653).

In addition to these two oral presentations, there also will be a poster presentation on SAR3419, the CD19-targeting ADC also in development through the Company’s collaboration with Sanofi.

  • Title: "Phase II Study of Anti-CD19 Antibody Drug Conjugate (SAR3419) in Combination with Rituximab: Clinical Activity and Safety in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma" (Abstract #4395).
  • Poster session #624: Dec. 9 at 6:00-8:00 pm CST.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla ®, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla ® is a registered trademarks of Genentech, Inc., a member of the Roche Group.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,983.75 -142.37 -0.79%
S&P 500 2,112.66 -8.13 -0.38%
NASDAQ 5,077.6670 -20.3090 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs